This is why I've sat on the sidelines.
For many companies, stem cells have been a case of "I've got this neat thing, let's see if it works on something", which is sometimes a viable strategy but requires a lot of studies and May amount to nothing.
A concern I have going forward is how they've mentioned the Novartis partnership at the bottom of the announcement today, specifically the Hart-Scott-Rodino antitrust improvements act.
I don't know much about the act but I did some googling.
This is why I've sat on the sidelines.For many companies,...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.05 |
Change
-0.020(1.88%) |
Mkt cap ! $1.193B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.08 | $1.02 | $6.417M | 6.155M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 960 | $1.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 25496 | 3 |
View Market Depth
| Last trade - 16.10pm 13/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.04 |
Change
-0.020 ( 2.49 %) |
||||
| Open | High | Low | Volume | ||
| $1.07 | $1.08 | $1.02 | 1459083 | ||
| Last updated 15.59pm 13/05/2024 ? | |||||
| MSB (ASX) Chart |